The use of new antiretroviral therapy in combination with chemotherapy

Current Opinion in Oncology

Volumn 9, Issue 5, 1997, Pages 455-464

  Tan, Benjamin ^a   Ratner, Lee ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTOKINE; DELAVIRDINE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; NEVIRAPINE; PREDNISONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VINCRISTINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG TOLERABILITY; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; KAPOSI SARCOMA; LYMPHOMA; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS TITRATION;

EID: 0030801204     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709050-00010     Document Type: Review

References (83)

1. Selik RM, Chu SY, Ward JW: Trends in infectious diseases and cancer among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995, 123:933-936.
2. Hirsch MS, D'Aquila RT: Drug therapy: summary of HIV replication cycle and available antiretroviral agents. N Engl J Med 1993, 328:1686-1695.
3. Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
4. Dragic T, Litwin V, Allaway GP, Martin SC, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
5. Feng Y, Broder C, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G-protein coupled receptor. Science 1996, 272:872-877.
6. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Foceille C, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
7. Hill CM, Littman DR: Natural resistance to HIV? Nature 1996, 382:668-669.
8. Miller RH, Sarver N: HIV accessory proteins as therapeutic targets. Nature Med 1997, 3:289-394.
9. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
10. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP: Quantification of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
11. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
12. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
13. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT: Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362:359-362.
14. Mansky LM, Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the fidelity of purified reverse transcriptase. J Virol 1995, 69:5087-5094.
15. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emimi EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
16. Havlir DV, Richman DD: Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996, 124:984-994, A good review on the concepts of viral burden and dynamics and its implications regarding therapeutic strategies, which must be effective against high levels of rapidly replicating virus that consist of many genetic variants.
17. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifsen JD: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
18. Kuritzkes DR: Plasma HIV RNA quantification. Improv Management HIV Dis 1996, 4:11-15. Correlates baseline viral load and changes in viral burden in patients receiving antiretroviral therapy with survival and disease progression.
19. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombes R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA: HIV viral load markers in clinical practice. Nature Med 1996, 2:625-629. Provides general guidelines and interim therapeutic goals for antiretroviral treatment using HIV-1 RNA plasma levels.
20. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
21. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
22. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD, for the Veterans Affairs Cooperative Study Group on AIDS. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
23. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA: Antiretroviral therapy for HIV infection in 1997. JAMA 1997, 277:1962-1969. Recommendations by an international panel on the treatment of HIV disease.
24. Sande MA, Carpenter CCJ, Cobbs CG, Homes KK, Sanford JP: Antiretroviral therapy for adult HIV-infected patients: recommendations from state-of-the-art conference. JAMA 1993, 270:2583-2589.
25. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New Engl J Med 1996, 335:1081-1090. A total of 2467 HIV-infected individuals randomly selected to receive zalcitabine alone, didanosine alone, or zidovudine plus zalcitabine or didanosme showing a 36%, 31%, and 23% decreased risk for progression in patients receiving zidovudine and didanosine, didanosine alone, or zidovudine and zalcitabine respectively, compared with zidovudine monotherapy.
26. Delta Coordinating Committee: Delta: a randomized double-blinded trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291. A total of 3207 HIV-infected patients randomly selected to receive zidovudine monotherapy or zidovudine plus didanosine or zalcitabine showed a 33% decrease in mortality in patients receiving zidovudine with didanosine and 21% decrease in mortality in patients receiving zidovudine and didanosine compared to zidovudine alone. The benefit in time to progression is seen only in patients with no prior antiretroviral therapy.
27. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors: a review for clinicians. JAMA 1997, 277:145-153. The latest comprehensive review on the use of protease inhibitors and its use in combination antiretroviral therapy.
28. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. New Engl J Med 1996, 335:1099-1106.
29. Katlama C, Ingrand D. Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H, for the Lamivudine European HIV working group: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:118-125.
30. Staszewski S, Loveday C, Picaso JJ, Dellamonica P, Skinhoj P, Johnson MA, Danner S, Harrigan PR, Hill AM, Verity L, McDade H, for the Lamivudine European HIV working group: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomized controlled comparison with zidovudine therapy. JAMA 1996, 276:111-117.
31. Eron JJ, Benoit SL, Jamsek J, MacArthur RD, Santiana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M, for the North American HIV working party: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New Engl J Med 1995, 333:1662-1669.
32. Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, Tsoukas C, Fallon MA, Self PL, Rubin M: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med 1996, 125:161-172.
33. Centers for Disease Control: 1993 Revised classification system for HIV Infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992, 41:1-19.
34. Staszewski S, Hill AM, Bartlett J, Eron JJ, Katlama C, Johnson J, Sawyer W, McDade H: Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997, 11:477-483.
35. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA, Rubin M: Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
36. Griffith BP, Brett-Smith H, Kim G, Mellors JW, Chako TM, Garner RB: Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis 1996, 173:1252-1255.
37. Spruance SS, Pavia AT, Mellors JW, Murphy R, Gathe J, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkie L: Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients: a randomized, double-blind, controlled trial. Ann Intern Med 1997, 126:355-363.
38. Rouleau D, et al.: A pilot, open-label study of the antiviral effect of Stavudine (d4T) and lamivudine (3TC) in advanced HIV disease [abstract]. International Conference on AIDS, Vancouver, British Columbia 1996, We.B.3137.
39. Spence RA, Kati WM, Anderson KS, Johnson KA: Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 1995, 267:988-993.
40. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS, AIDS Clinical Trials Group Protocol 241 Investigators: Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 12:1019-1030.
41. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, et al.: A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. New Engl J Med 1995, 333:1528-1533.
42. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH: Role of cytochrome P450 3A4 in human metabolism of MK639, a potent human immunodeficiency virus protease inhibitor. Drug Metabolism and Disposition 1996, 24:307-314.
43. Schmit JC, Ruiz L, Clotet B, Raventos A, Tor J, Leonard J, Desmyter J, De Clerq E. Vandamme AM: Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996, 10:995-999.
44. Condra JH, Holden DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
45. Markowitz M, Cao Y, Hurley A: Triple therapy with AZT, 3TC and ritonavir in 12 subjects newly infected with HIV-1 [abstract]. In Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.933.
46. Gulick R, Mellors J, Havlir D: Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine [abstract]. In Programs and abstracts of the third conference on retroviruses and opportunistic infections. January 28-February 1, 1996; Washington, DC.
47. Biggar RJ, Rabkin CS: The epidemiology of AIDS-related neoplasms. Hemtol/Oncol Clin North Am 1996, 10:997-1010.
48. Friedman-Kien AE, Saltzman BR, Cao YZ: Kaposi's sarcoma in HIV-negative homosexual men [letter]. Lancet 1990, 335:168.
49. Lyter DW, Bryant J, Thackeray R, Rinaldo CR, Kingsley LA: Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol 1995, 13:2540-2546.
50. Marsh JW, Herndier B, Tsuzuki A, Ng V, Shiramizu B, Abbey N, McGrath M: Cytokine expression in large cell lymphoma associated with acquired immunodeficiency syndrome. J Interferon Cytokine Res 1995, 15:261-268.
51. Ott M, Emiliani S, Van Lint C, Herbein G, Lovett, J, Chirmule N, McCloskey T, Pahwa S, Verdin E: Immune hyperactivation of HIV-infected T cells mediated by Tat and the CD28 pathway. Science 1997, 275:1481-1485.
52. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990, 345:84-86.
53. Barillari G, Fiorelli V, Gendelman R, Colombini S, Bohan Morris C, Sgadari C, Markham P, Gallo RC, Ensoli B: HIV-1 Tat protein enhances angiogenesis and Kaposi's sarcoma development triggered by inflammatory cytokines or bFGF by engaging the ccvβ3 integrin [abstract 68]. J Acq Imm Def Syndr Hum Retrov 1997, 14:A33.
54. Harrington WJ, Sieczkowski L, Sosa C, Chan S, Cai JP, Cabrai L, Wood C: Activation of HHV-8 (KSHV) by HIV-1 Tat [abstract 69]. J Acq Imm Def Syndr Hum Retrov 1997, 14:A33.
55. Emilie D, Coumbaras J, Raphael M, Devergne O, Delecluse HJ, Gisselbrecht C, Michiels JF, Van Damme J, Taga T, Kishimoto T: Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus seronegative patients. Blood 1992, 80:498-504.
56. Mack KD, Wei R, Herndier B, Shiramizu B, Hurt M, Abbey N, Gascon R, Elbaggari A, McGrath MS: HIV insertional cis-activation of the protooncogene c-fes in AIDS associated lymphomagenesis [abstract 114]. J Acq Imm Def Syndr Hum Retrov 1997, 14:A44.
57. Baselga J, Krown SE, Telzak EE, Filippa DA, Straus DJ: Acquired immune deficiency syndrome-related pulmonary non-Hodgkin's lymphoma regressing after zidovudine therapy. Cancer 1993, 71:2332-2334.
58. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, Ziegler J, Volberding PA: AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989, 261:719-724.
59. Knowles DM, Chamulak GA, Subar M, Burke JS, Dugan M, Wernz J, Slywotzky C, Pelicci PG, Dalla-Favera R, Raphael B: Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): the New York University Medical Center experience with 105 patients (1981-1986). Ann Intern Med 1988, 108:744-753.
60. Sparano JA, Wiernik PH, Strack M, Leaf A, Becker NH, Sarta C, Carney D, Elkind R, Shah M, Valentine ES: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma 1994, 14:263-271.
61. Sparano JA, Hu X, Wiernik PH, Sarta C, Reddy D, Hanau L: Opportunistic infection and immunologic function in patients with AIDS-associated lymphoma treated with chemotherapy [abstract 87]. J Acq Imm Def Syndr Hum Retrov 1997, 14:A38.
62. Caumes E, Guermonprez G, Katlama C, et al.: AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin. AIDS 1992, 6:1483-1487.
63. Levine AM, Wernz J, Kaplan L, Rodman N, Cohen P, Metroka C, Bennett JM, Rarick MV, Walsh C, Kahn J: Low dose chemotherapy with CNS prophylaxis and zidovudine (AZT) maintenance for AIDS-related lymphoma: follow-up data from a multiinstitutional trial. JAMA 1991, 266:84-88.
64. Kaplan L, Kahn J, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracy J, Mills J, Volberding PA: Clinical and virologic effects of rhGMCSF in patients receiving chemotherapy for HIV-associated NHL: results of a randomized trial. J Clin Oncol 1991, 9:929-940.
65. Gabarre J, Lepage E, Thyss A, Tubiana R, Bastion Y, Schlaiffer D, Sebban C, Ribrag V, Fereres M, Raphael M: Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma. Ann Oncol 1995, 6:1025-1032.
66. Manome Y, Yao XJ, Kufe DW, Cohen EA, Fine HA: Selective effects of DNA damaging agents on HIV long terminal repeat activation and virus replication in vitro. J AIDS 1996, 11:109-116.
67. Little R, Franchini G, Pearson D, Elwood P, Steinberg S, Yarchoan R, Wilson WH: HIV viral burden during EPOCH chemotherapy for HIV-related lymphomas [abstract 104]. J Acq Imm Def Syndr Hum Retrov 1997, 14:A42.
68. Lee FC, Leiblin A, Carden J, Miles S, Mitsuyasu R: Viral load changes in patients undergoing chemotherapy for AIDS-KS. J Acq Imm Def Syndr Hum Retrov 1997, 14:A42.
69. Gill PS, Miles SA, Mitsuyasu RT, Montgomery T, McCarthy S, Espina BM, Feldstein M, Levine AM: Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1994, 8:1695-1699.
70. Mitsuyasu RT, Gill P, Paredes J, et al.: Combination chemotherapy, adriamycin, bleomycin, vincristine (ABV) with dideoxyinosine (ddI) or dideoxycytidine (ddC) in advanced AIDS-related Kaposi's sarcoma (ACTG 163) [abstract]. Proc Am Soc Clin Oncol 1995, 14:289.
71. Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, Henry DH, Mason B, Ratech H, Dutcher JP: Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgastrim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol 1996, 14:3026-3035. Demonstrates that the combination of didanosine with CDE chemotherapy was well tolerated with decreased risk for myelosuppression and no increased risk for peripheral neuropathy. The CD4 cell count decreased and viral load in the majority of patients increased.
72. Levine AM, Tulpule A, Espina B, Boswell W, Buckley J, Rasheed S, Stain S, Parker J, Nathwani B, Gill PS: Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma: effect on human immunodeficiency virus and serum interleukin-6 over time. Cancer 1996, 78:517-526. The use of nonmyelosuppressive antiretroviral agent zalcitabine was well tolerated when combined with antilymphoma agents.
73. Kivisto KT, Kroemer HK, Eichelbaum M: The role of human cytochrome p450 in the metabolism of anticancer agents. British Journal of Clinical Pharmacology 1995, 40:523-530.
74. Cohen C, Sun E, Cameron W, et al.: Ritonavir-saquinavir combination in the treatment of HIV-infected patients [abstract LB7b]. In Programs and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18, 1996, New Orleans.
75. Schapiro JM, Winters MA, Stewart F, Efron B, Morris J, Kozal MJ, Merigan TC: The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
76. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruchi A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
77. Pollard R, Peterson D, Hardy D: Stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot, randomized, double-blinded trial. XIth International Conference on AIDS. Vancouver, British Columbia 1996.
78. Markowitz M, Cao Y, Hurley A, et al.: Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naive subjects chronically infected with HIV-1 [abstract]. XIth International Conference on AIDS, Vancouver, British Columbia 1996.
79. Massari R, Conant M, Mellors JW, et al.: A phase II open-label randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (ddl) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients [abstract]. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC 1996.
80. 3 [abstract]. XI International Conference on AIDS, Vancouver, British Columbia 1996.
81. Gathe J, Burkhardt B, Hawley P, Conant M, Peterkin J, Chapman S: A randomized phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine vs stavudine alone [abstract]. XI International Conference on AIDS. Vancouver British Columbia, 1996.
82. 3: AIDS Clinical Trials Group protocol 208. J Infect Dis 1996. 172:1379-1383.
83. Devineni D, Gallo JM: Zalcitabine: clinical pharmacokinetics and efficacy. Clin Pharmacokin 1995, 28:351-360.